1. Introduction {#s0005}
===============

Functional magnetic resonance imaging (fMRI) has made important contributions to our understanding of post-stroke brain changes. fMRI can provide valuable insight in terms of characterizing brain plasticity changes as well as the prediction of outcomes and assessment of recovery after stroke ([@bb0050], [@bb0100], [@bb0245]). However, there is growing concern over the integrity of the blood oxygenation level-dependent (BOLD) signal, which is sensitive to changes in cerebral blood flow and volume in addition to the rate of oxygen metabolism, in stroke patients and other groups who may exhibit impairments in cerebrovascular reactivity (CVR)---the ability of cerebral microvasculature to modulate blood flow in response to vasodilatory stimuli, such as neural activity ([@bb0065], [@bb0085], [@bb0155]). Such impairments may manifest as an uncoupling of neural and vascular activity that can preclude the hemodynamic response from reaching a designated threshold during a typical task-fMRI paradigm, especially when assumed to match that of young, healthy subjects ([@bb0015], [@bb0165]). The resulting false negatives in the BOLD signal can be misleading to both researchers and clinicians attempting to map changes in brain function after stroke. It is therefore crucial to assess the risk of neurovascular uncoupling (NVU) in stroke patients, and in turn, the validity of BOLD fMRI in this group.

Many studies have sought to assess the validity of fMRI in cerebrovascular patients, often observing a delayed, attenuated, or absent hemodynamic response to behavioral tasks with fMRI ([@bb0035], [@bb0150], [@bb0170], [@bb0195]), even when a neural response is measured by other means ([@bb0015], [@bb0025], [@bb0040], [@bb0165], [@bb0210]). However, a majority have focused almost exclusively on the chronic stage ([@bb0040], [@bb0035], [@bb0150], [@bb0165], [@bb0210]), several weeks to months from the stroke. Because functional imaging is often performed just days after a stroke (i.e., at the acute stage), it is critical to determine if NVU is already a significant concern at this point. Since CVR may continue to change throughout the course of stroke recovery ([@bb0020], [@bb0220], [@bb0250]), it is plausible that NVU may be only transient in stroke patients, increasing confidence in fMRI data obtained either before or after a certain risk period. Two longitudinal evaluations of the BOLD signal after stroke have supported this notion, suggesting that NVU risk after stroke is time-sensitive and may be minimal within the first few days of stroke ([@bb0010], [@bb0025]). However, the neural variability resulting from conventional fMRI tasks presents a challenge for identifying NVU in this way, and such an approach is inherently limited to the functional region expected to be activated by the task.

In recent years, more robust means for detecting NVU risk have emerged. Specifically, breath-hold CVR mapping, which emerged as a more convenient alternative to other hypercapnic methods such as exogenous CO~2~ administration, is continuing to garner attention for clinical research and application---particularly to augment functional maps obtained from presurgical tumor patients ([@bb0185], [@bb0190]). This non-invasive technique simply requires patients to hold their breath for short intervals inside the MR scanner. Regions of impaired CVR are not as effective in modulating blood flow in response to the induced hypercapnia and can thus be visualized as areas void of activity in the resulting fMRI maps ([@bb0185]). This method has previously been used at the group level to confirm the deleterious effects of aging on CVR ([@bb0095], [@bb0130]), although to our knowledge it has been implemented just twice previously for the same purpose in stroke patients ([@bb0080], [@bb0240]), the focus being on the subacute and chronic stages.

Thus, the goal of the present study was to quantitatively assess CVR and determine the validity of fMRI in stroke patients at the acute stage, defined in our study as less than ten days after stroke. BOLD parameters computed from a breath-hold task were compared between stroke patients and healthy controls at the group level to identify any stroke-related deficits in CVR that could give rise to NVU. These results are obtained through two separate analyses in order to compare two common approaches to accounting for the extended delay of the vascular response to hypercapnia relative to neural activity---a standard adjustment of the breath-hold model response for all subjects (standard delay) (as in ([@bb0075])) and an adjustment optimized on an individual basis (subject-wise delay) (as in ([@bb0045])).

Based on the findings of Binkofski and Seitz ([@bb0025]) and Altamura et al. ([@bb0010]), we hypothesized that CVR is not yet impaired at a level detectable by fMRI at the acute stage of stroke. Thus, since CVR deficits have been regularly implicated in healthy aging ([@bb0065], [@bb0200]), we predicted that global CVR would be reduced in stroke patients compared to young controls but would not differ from older, age-matched controls. Additionally, although the degree of CVR impairment has been found to be especially pronounced in the lesioned hemisphere ([@bb0010], [@bb0025], [@bb0150], [@bb0165]), we expected to observe no differences in CVR between the ipsilesional and contralesional hemispheres of stroke patients at this early stage.

2. Methods {#s0010}
==========

2.1. Subjects {#s0015}
-------------

Twenty-two acute stroke patients (ages 44--75 years, mean = 59 years, 14 male) ([Table 1](#t0005){ref-type="table"}) were included in the study, originally recruited for an ongoing longitudinal project. Inclusion criteria were at least 18 years of age, ability to provide written informed consent, and initial scan within 10 days of stroke. Exclusion criteria were history of psychiatric illness, confounding neurological disorders, drug abuse, and contraindications to MRI. Twenty-two age-matched healthy controls were also included in the study (ages 50--74 years, mean = 59, 10 male), as well as a group of 22 younger healthy controls (ages 18--27 years, mean = 22, 11 male). The study was conducted in accordance with a protocol approved by the local Health Sciences Institutional Review Board. All subjects provided written informed consent.

2.2. Data collection {#s0020}
--------------------

All imaging data were obtained on GE 750 3T MRI scanners (GE Healthcare, Waukesha, WI) equipped with an eight-channel head coil. T1-weighted axial anatomical slices were acquired at the beginning of each session following an FSPGR BRAVO sequence (TR = 8.132 ms, TE = 3.18 ms, TI = 450 ms, 256 × 256 matrix, 156 slices, flip angle = 12°, FOV = 25.6 cm, slice thickness = 1 mm). Functional data were acquired via echo-planar T2\*-weighted imaging (TR = 2.0 s, 40 slices, 90 volumes, TE = 22 ms, FOV = 22.4 cm, flip angle = 60°, voxel dimensions 3.75 × 3.75 × 4.0 mm^3^).

Each breath-hold scan followed a block design consisting of four 20-s, end-expiration blocks alternating with four 20-s blocks of rest, for a total scan length of 3 min. Subjects were instructed to begin each task block with a moderate breath.

2.3. Data analysis {#s0025}
------------------

All preprocessing of imaging data was performed within the Analysis of Functional Neuroimages (AFNI) suite ([@bb0055]), except where noted. Subject-specific gray matter masks were created via automated segmentation of the skull-stripped anatomical volumes using FSL\'s FAST (FMRIB Software Library, Oxford, UK) ([@bb0255]). Functional data were first aligned to the anatomical and normalized to standard Montreal Neurological Institute (MNI) space. The first four volumes were discarded to allow for steady-state imaging. Images were then resampled to 3.0 mm isotropic, despiked, volume-registered, and spatially smoothed using a 4-mm full-width at half-maximum Gaussian kernel. The time series within each voxel was scaled to percent signal and estimated in a general linear model with a canonical gamma variate hemodynamic response function (HRF) convolved with a boxcar reference waveform and six rigid-body motion parameters and their derivatives regressed. A composite estimate of head motion was calculated for each subject as the square root of the sum of squares (Euclidean norm) of the twelve motion parameters\' (three translational and three rotational) derivatives ([@bb0125]). High-motion time points (Euclidean norm exceeding 0.3) were censored in the GLM.

2.4. Breath-hold analyses: Standard delay and subject-wise delay {#s0030}
----------------------------------------------------------------

In an initial analysis, the model HRF was delayed by a standard amount for all subjects (standard delay). A wide range of values have previously been used for this purpose, from as low as 7 s ([@bb0075]) up to 12 s ([@bb0135]). Given the advanced age of many of the subjects included in the study, we tested a relatively lengthy delay of 11 s for all subjects.

In a separate analysis, the Hilbert transform (AFNI plugin *3ddelay*) was used to approximate, at each voxel, the temporal shift of the model HRF needed to best fit the voxel\'s time course. These delays were averaged over gray matter and incorporated into the model for each subject (subject-wise delay) in order to account for the inter-subject variability in the breath-hold vascular response and potential delays due to slower-responding vasculature in older controls or stroke patients.

2.5. Breath-hold measures and statistical tests {#s0035}
-----------------------------------------------

For both the standard and subject-wise analyses, magnitude of activation from the breath-hold task was derived from the beta-weights for the HRF, which approximate BOLD percent signal change during the task, while activation volume was determined as the number of voxels surpassing a liberal threshold of *p* \< 0.01 (uncorrected) ([@bb0080]). The mean delay of the HRF obtained from *3ddelay* was also averaged over gray matter and compared between groups. One-way ANOVAs were performed separately for the magnitude, extent, and delay of BOLD activation, as well as gray matter volume, among the three groups. To ensure that ipsilesional impairments in CVR were not overlooked due to averaging with intact contralesional CVR, hemispheric comparisons in stroke patients were performed. Two-tailed paired t-tests were used to compare the above measures between the ipsilesional and contralesional hemispheres of patients. Paired t-tests were also used to compare measures for each group between the two analyses (standard delay versus subject-wise delay). A *p* value of ≤ 0.05 was considered statistically significant for all tests. For ANOVAs, this was determined by Fisher\'s least significant difference (LSD) post-hoc test. Statistics are represented as mean ± standard deviation.

3. Results {#s0040}
==========

3.1. Motion during breath-hold task {#s0045}
-----------------------------------

As described above, a composite measure of head motion, the Euclidean norm, was calculated for each subject. An ANOVA revealed significant between-group differences in the mean of this motion estimate (young controls = 0.09 ± 0.03 mm, old controls = 0.11 ± 0.05 mm, stroke = 0.16 ± 0.07 mm; *F*~(2,\ 63)~ = 9.94, *p* \< 0.001). As detailed in the previous section, these differences were minimized through an aggressive motion scrubbing approach in which high-motion time points were censored before HRF fitting, in addition to the regression of six motion parameters and their derivatives.

3.2. Gray matter volume {#s0050}
-----------------------

The volume of the gray matter mask created for each subject was, on average, 85.4 ± 3.7 cm^3^ for young controls, 78.4 ± 5.9 cm^3^ for old controls, and 76.4 ± 4.9 cm^3^ for patients (*F*~(2,\ 63)~ = 20.1, *p* \< 0.001). Due to these being significantly different, group activation volumes are reported as percentages of the average size of the gray matter mask for each group ([@bb0225]).

[Fig. 1](#f0005){ref-type="fig"} displays group activation maps for both analyses (standard delay and subject-wise delay). The figure shows large differences in activation volume among the three groups when projected onto a standard MNI mask for both standard and subject delayed approaches. However, for quantitative analysis below, much of this was accounted for by using gray matter masks specific to these different groups.

3.3. Standard delay {#s0055}
-------------------

There were significant differences in magnitude of BOLD activation, calculated as the average percent signal change across gray matter (*F*~(2,\ 62)~ = 3.52, *p* = 0.036). Whereas young controls (1.06 ± 0.27) did not differ from old controls (0.92 ± 0.27; *p* = 0.090) or patients (1.14 ± 0.30; *p* = 0.369), the BOLD magnitude of patients was significantly greater than that of old controls (*p* = 0.011) ([Fig. 2](#f0010){ref-type="fig"}). Differences in activation volume also reached significance (*F*~(2,\ 63)~ = 3.18, *p* = 0.048) as, on average, a significantly greater percentage of gray matter voxels were activated in young controls (44.8 ± 19.8%) compared with old controls (25.9 ± 25.2%; *p* = 0.015) ([Fig. 3](#f0015){ref-type="fig"}). Differences between young controls and patients (37.4 ± 29.4) were not significant (*p* = 0.329), nor were those between old controls and patients (*p* = 0.133). Magnitude and activation volume in the ipsilesional hemisphere of stroke patients (1.18 ± 0.39 and 37.0 ± 29.0%, respectively) were not significantly different from the contralesional hemisphere (1.18 ± 0.40 and 38.0 ± 30.3%) (magnitude: *t*~(21)~ = 0.08, *p* = 0.939; activation volume: *t*~(21)~ = 0.73, *p* = 0.476).

3.4. Subject-wise delay {#s0060}
-----------------------

Young controls showed the shortest delay in hemodynamic response (11.2 ± 2.4 s), followed by stroke patients (11.3 ± 2.1 s), while the longest delay was observed in old controls (12.6 ± 2.0 s); however, these differences yielded only a non-significant trend (*F*~(2,\ 63)~ = 2.69, *p* = 0.076) ([Fig. 4](#f0020){ref-type="fig"}). Magnitude of BOLD activation did not significantly differ between the three groups (young controls = 1.13 ± 0.20, old controls = 1.12 ± 0.39, stroke patients = 1.25 ± 0.32; *F*~(2,\ 63)~ = 1.13, *p* = 0.329) ([Fig. 2](#f0010){ref-type="fig"}). However, there were significant between-group differences in activation volume in the subject-wise delay analysis (*F*~(2,\ 63)~ = 3.75, *p* = 0.029), with young controls (49.7 ± 16.7%) having a significantly greater extent of activation than old controls (29.8 ± 22.6%) (*p* = 0.008), although not stroke patients (39.1 ± 31.0%) (*p* = 0.149) ([Fig. 3](#f0015){ref-type="fig"}). The difference between old controls and patients did not reach significance (*p* = 0.207). The average hemodynamic delay did not differ between the ipsilesional (11.2 ± 2.1 s) and contralesional (11.3 ± 2.1 s) hemispheres of stroke patients (*t*~(21)~ = 0.23, *p* = 0.822). Further, as in the standard delay analysis, there were no significant differences in either magnitude or activation volume between the ipsilesional (magnitude = 1.24 ± 0.32; activation volume = 38.8 ± 30.5%) and contralesional (magnitude = 1.23 ± 0.34; activation volume = 39.4 ± 31.9%) hemispheres of stroke patients (magnitude: *t*~(21)~ = 0.15, *p* = 0.884; activation volume: *t* = 0.55, *p* = 0.587).

3.5. Comparison of analyses: Standard delay vs. subject-wise delay {#s0065}
------------------------------------------------------------------

The differences in magnitude of activation yielded by the standard delay and subject-wise delay analyses were not significant for young controls (*t*~(21)~ = 1.18, *p* = 0.250) or stroke patients (*t*~(21)~ = 1.03, *p* = 0.317), although using an individualized value for the delay gave a significantly greater magnitude for old controls (*t*~(21)~ = 3.35, *p* = 0.003). Activation volume did not significantly change between the analyses for any of the groups; however, unlike for young controls (*t*~(21)~ = 1.35, *p* = 0.191) and patients (*t*~(21)~ = 1.28, *p* = 0.215), there was a non-significant trend towards increased activation volume in the subject-wise delay analysis for old controls (*t*~(21)~ = 1.86, *p* = 0.077).

4. Discussion {#s0070}
=============

fMRI is a powerful tool that is commonly used to non-invasively localize neural activity in the human brain, although its clinical application has been limited for a variety of reasons ([@bb0120], [@bb0180]). One limitation, NVU, may compromise the validity of the BOLD signal in several patient populations, including brain tumor ([@bb0110], [@bb0235]), Alzheimer\'s disease ([@bb0115]), cerebrovascular disease ([@bb0060], [@bb0195], [@bb0205]), and healthy aging ([@bb0065], [@bb0200]). There is currently a limited understanding of the sequence of events that link neural activity to a hemodynamic response, but in theory, a disruption at any stage in this sequence could result in NVU ([@bb0105], [@bb0185]).

Many studies have indicated the presence of NVU in stroke patients, although it remains unclear exactly how soon after a stroke NVU becomes a significant concern. fMRI has been used to characterize brain changes from just days after a stroke to several months afterward, as results from functional imaging studies have informed our understanding of the prolonged time course of stroke recovery (e.g., ([@bb0215], [@bb0245])). In the present study, we focused on acute stroke patients less than 10 days from stroke. We used a breath-hold task to quantify any disparities in CVR in these patients at the group level relative to healthy controls. Moreover, we analyzed the resulting BOLD response by fitting it with an HRF that was either delayed by a standard amount for all subjects, as is often done to account for the slower vascular response to hypercapnia versus neural activity, or by an amount that was optimized for each subject, accounting for differences in this hemodynamic delay.

Our standard delay analysis, interestingly, revealed a significantly greater magnitude of the breath-hold response in patients compared to old controls. The reason for this is unclear, but this could be due to a combination of the poor fit of the standard delay model for old controls as well as increased motion in the patient group, although a stringent motion censoring approach was undertaken. The subject-wise delay did not reveal any such differences in magnitude. In both analyses, the activation volume of young controls was greater than old controls but not patients. Importantly, neither analysis indicated impaired CVR in the patient group beyond that of age-matched controls. Furthermore, we observed no differences in the breath-hold response between the ipsilesional and contralesional hemispheres of patients. The findings from our study suggest that fMRI may still be valid at the acute stage of stroke, particularly for group comparisons with healthy age-matched subjects.

When considered in the context of existing stroke literature, it may be that NVU first appears at some point beyond the acute stage. This idea is supported by two longitudinal evaluations of the BOLD signal after stroke. Binkofski and Seitz ([@bb0025]) found task-induced activation volume to be transiently decreased 2--4 weeks after a stroke, relative to both 1 week and 1 month after the stroke, while transcranial magnetic stimulation was used to verify neural responses at each time point. Similarly, dynamic BOLD activation was described by Altamura et al., who observed hemodynamic impairment at the subacute, but not the acute, stage. Although the subacute range in their study, 5--12 days after stroke, had considerable overlap with the present study, the average time since stroke in the present study falls just below this range. It is possible that cerebrovascular changes begin to take place during this range, becoming more apparent in the latter part. More longitudinal studies are necessitated to address such questions.

In addition to our observations in stroke patients, our results from both analyses also support the notion that increasing age adversely impacts the BOLD signal ([@bb0065], [@bb0200], [@bb0230]). While fMRI still receives widespread use for elderly subjects, comparisons with younger subjects should acknowledge differences in vasculature. The purpose of our standard versus subject-wise delay analysis was to draw attention to the practice of shifting the breath-hold HRF model by an equivalent amount for a group of subjects with variable CVR (e.g., [@bb0075], [@bb0135]), rather than modeling the response on an individual basis. Although both approaches yielded the same pattern of results, the more individualized, subject-wise delay analysis showed significantly increased activation volume in old controls---the group with the greatest hemodynamic delay. This finding highlights the importance of the delay chosen for analysis of breath-hold data, as a standard HRF delay used for subjects of varying ages may inadvertently favor younger subjects when determining active voxels. This may represent a larger problem in cognitive neuroscience research, in which a standard model based on young healthy subjects is regularly used for all subjects ([@bb0005], [@bb0065], [@bb0090]). Such modeling may overlook neural activity in non-typical subjects that induces a measureable but less predictable vascular response. The use of an end-tidal CO~2~ trace as a GLM regressor has been promising for improving the accuracy of breath-hold response modeling ([@bb0045], [@bb0080], [@bb0160]), although this does not apply to the modeling of traditional fMRI task paradigms.

4.1. Breath-hold CVR mapping in stroke {#s0075}
--------------------------------------

The present study utilized breath-hold CVR mapping, which is only starting to become utilized in the stroke population. The primary use of this technique has been for evaluating hemodynamic responsiveness in patients -- particularly neurosurgical patients -- in order to identify regions in which the BOLD signal from a task can be expected to be attenuated ([@bb0185]). Its correspondence with other validated methods for evaluating CVR has been demonstrated ([@bb0030], [@bb0145]). In stroke patients, the importance of such a procedure becomes especially apparent when attempting to compare neuroimaging data with healthy controls or evaluate changes to functional networks over time. To our knowledge, just two published studies have utilized a breath-hold task in stroke patients; interestingly, like the present study, both failed to observe perturbed CVR. In an fMRI study of recovery from aphasia, van Oers et al. ([@bb0240]) implemented a breath-hold task to validate their comparisons from functional imaging by showing that subacute and chronic stroke patients did not differ from controls in CVR. Recently, Geranmayeh et al. ([@bb0080]) also found no differences in CVR in the healthy tissue of subacute and chronic stroke patients and controls. However, the negative findings of these studies contradict much of the literature in chronic stroke. Perhaps more importantly, though, these studies demonstrate the ease and efficacy of a breath-hold task to increase confidence in group functional imaging studies involving chronic stroke patients. Similarly, our study serves this purpose for acute patients.

Given that all three breath-hold studies have indicated CVR to be unaffected in stroke, it is important to note that intact CVR is not equivalent to intact neurovascular coupling. It is plausible in some cases that the ability of vascular smooth muscle cells to modulate blood flow in response to hypercapnia is preserved at the same time that the response to extravascular (e.g., neural) stimulation is compromised. While CVR-based methods of predicting NVU assume a common mechanism to underlie deficits in both, such as an overall reduced capacity for vasodilation, NVU may actually be the result of dysfunction at an earlier stage of the functional hyperemic process---anywhere from the release or synthesis of vasoactive agents in response to neural activity to the binding of these agents, to their corresponding pathways that would otherwise result in vasodilation ([@bb0085]). BOLD CVR mapping does not exactly test neurovascular coupling, per se, and thus may be of little use in such cases of upstream neurovascular dysfunction ([@bb0070], [@bb0185]). This possibility deserves particular consideration in ischemic stroke due to the selective changes in the neurovascular unit that may occur. For example, astrocytes, which link synaptic activity to capillaries and arterioles and thus play a critical role in neurovascular coupling, are often damaged in the stroke event or functionally altered afterward ([@bb0175]). To the best of our knowledge, there has not yet been a demonstration of impairment at an earlier stage of the coupling process with a preserved vasodilatory response to hypercapnia, but this remains a theoretical possibility.

4.2. Limitations and future directions {#s0080}
--------------------------------------

Our study had multiple experimental limitations that should be taken into consideration. For one, it is known that differences in breath-hold task performance can confound CVR comparisons ([@bb0140]). Thus, it may be important in future studies to collect physiological data and CO~2~ recordings in order to verify proper performance of all study subjects on the breath-hold task and improve estimates of CVR ([@bb0160]). In the present study, because no differences in CVR were observed between patients and age-matched controls, it is unlikely that performance was a major issue in the patient group.

Head motion can also become an important concern when working with patient imaging data. The patient group in the present study exhibited more head motion than both groups of controls, and old controls exhibited more head motion than young controls. Although we took an aggressive approach to minimize the risk of head motion obscuring differences in CVR, task-related motion may still have impacted the data, potentially increasing the number of voxels exhibiting task-associated activity as well as the estimated magnitude of BOLD activation. This possibility is acknowledged and highlights one of the most persistent challenges in fMRI research and, in particular, its clinical application.

Finally, the heterogeneity in our patient sample with respect to factors such as type of stroke, location, lesion volume, treatment, and time after stroke onset may have contributed to the high variability observed, making an effect more difficult to identify. For example, differences may exist between cortical and subcortical or supratentorial and infratentorial strokes, or strokes in regions supplied by different major arteries, all of which are included in our sample; however, the extent to which these would differentially affect CVR is unknown. Moreover, changes in the brain can occur quickly in the days following stroke onset, and so the variability in time after onset in our sample could potentially represent different stages in the recovery process. More generally, the course of CVR may be radically different from patient to patient for a number of reasons, and it is possible that any impairments in CVR were averaged out at the group level. Reduced CVR may also be highly focal to the lesion and could have been overlooked when averaging over whole-brain gray matter. To account for this, we compared ipsilesional and contralesional CVR at a group level and confirmed our negative findings, although it is possible that even averaging over a hemisphere is enough to mask reduced CVR inside and proximal to the lesioned area. In short, the highly variable results among patients in our study still warrant precaution when interpreting data from individual patients. In the future, to overcome some limitations of the present study, it would be useful to perform similar analyses in a more homogenous and larger stroke sample.

5. Conclusion {#s0085}
=============

Here we used a breath-hold task to evaluate CVR shortly after stroke. NVU has received increased attention in recent years, particularly in patient populations such as stroke. However, our findings suggest that NVU due to compromised CVR is likely not a serious concern for group comparisons of fMRI data between acute stroke patients and age-matched controls. Thus, group differences in these studies can likely be attributed to brain activity differences. Nonetheless, given the effect of stroke on vasculature and the high variability in CVR observed here, researchers and clinicians should remain cognizant of the limitations of fMRI when dealing with patients at any stage of stroke. In future studies, it will be useful to include more homogenous patient samples and to obtain CO~2~ recordings to improve the accuracy of breath-hold data.
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![Average breath-hold fMRI group maps from the standard delay (left) and subject-wise delay (right) analyses for young controls (top), old controls (middle), and patients (bottom) overlaid on MNI 152 template. Functional data shown at *p* \< 0.05 with a minimum cluster size of 60 voxels. 11 of the 22 stroke maps were flipped so that all lesioned hemispheres were on the left side (displayed to the right in this figure).](gr1){#f0005}

![Mean percent signal change in gray matter observed in the BOLD signal during the breath-hold task. Group averages are shown for both standard delay (left) and subject-wise delay (right) analyses. One patient data point from the standard delay was treated as an outlier as it was greater than three standard deviations from the group mean and is not represented here. ^⁎^*p* \< 0.05.](gr2){#f0010}

![Mean activation volume (as a percentage of gray matter) resulting from the breath-hold task, as calculated from the standard delay (left) and subject-wise delay (right) analyses. \* *p* \< 0.05.](gr3){#f0015}
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###### 

Patient characteristics.

Table 1

  Patient   Sex   Age (years)   Time since stroke (days)   Lesion location                        NIH Stroke Scale score   Treatment
  --------- ----- ------------- -------------------------- -------------------------------------- ------------------------ -----------
  1         M     75            6                          C; L occipital                         1                        tPA + ST
  2         M     69            4                          L cerebellum, occipital                0                        ST
  3         M     74            7                          C; R temporal, occipital               1                        ST
  4         F     44            5                          C; L insula, frontal                   7                        ST
  5         M     45            3                          L cerebellum                           2                        ST
  6         M     55            3                          C; L MCA and MCA/PCA border            0                        ST
  7         M     62            9                          C; L parietal                          0                        ST
  8         M     58            5                          C; L corticospinal tract, cerebellum   0                        ST
  9         F     59            7                          C; R MCA                               2                        tPA + ST
  10        M     59            4                          C; R MCA                               2                        tPA + ST
  11        M     57            3                          SC; R pontine                          2                        ST
  12        M     63            5                          SC; R pontine                          0                        ST
  13        F     47            9                          C; R frontal                           0                        ST
  14        F     58            7                          C; L frontal                           1                        ST
  15        F     59            2                          C; L posterior insular, parietal       2                        ST
  16        F     46            0                          R cerebellum                           2                        ST
  17        M     67            5                          SC; L lateral medulla                  0                        ST
  18        M     63            3                          C; R MCA                               0                        ST
  19        F     57            6                          L cerebellum                           1                        ST
  20        M     63            2                          SC; L posterior putamen                2                        ST
  21        M     46            3                          C; R occipital                         0                        tPA + ST
  22        F     67            5                          C; R MCA                               4                        tPA + ST

C, cortical; SC, subcortical; L, left; R, right; MCA, middle cerebral artery; PCA, posterior cerebral artery; tPA, tissue plasminogen activator; ST, standard of care stroke treatment (in most cases consisted of antiplatelet agent (e.g., aspirin, clopidogrel), anticoagulant (e.g. heparin, warfarin), anti-hypertensive (e.g., beta blocker, angiotensin-converting-enzyme inhibitor, and/or statin (e.g., simvastatin, pravastatin)).
